Mario Cornacchione, DO, MS, FAAFP

Recent publications

Publications

• Addiction: A pilot study of an intervention to influence medical students’ attitudes and response to substance abuse within themselves, medical student peers and physicians. Teaching and Learning in Medicine Volume 27, Issue 2, April 2015, pages 226-232
• Martin H, Slyk MP, Deymann S, Cornacchione MJ. A Safety Profile of Risperdone and Olanzapine in a Long Term Care Dementia Population. J Am Med Dir Assoc. 2003 Jul-Aug;4(4):183-8.
• Cornacchione M. Insomnia in the Long Term Care Setting: Assessment & Management. J Am Med Dir Assoc. Nov./Dec. 2000, Vol.1, No.6.
• Cornacchione, M., Slusser, P., Depression in the Long Term Care Setting. Nursing Home Medicine, Vol. 2, No. 2, 1992.
• Chair, Co Author/ Clinical Practice Guidelines: COPD in Long Term Care. American Medical Directors Association, 2010
• Co-Author/ Clinical Practice Guidelines: Delirium & Acute Problematic Behavior in the Long Term Care Setting. American Medical Directors Association, 2007
• Co-Author/ Clinical Practice Guidelines: Dementia Care in Long Term Care. American Medical Directors Association, 2007
  
  

Editorial boards

Journal of Parkinson’s Disease and Alzheimer’s Disease

Presentations

• Linking IRAT and GRAT Questions Through Clinical Concepts.
  David B. Averill¹, Mario Cornacchione¹, Magrit Shoemaker¹, Devon Bremer¹ ,Kal Winston
  Presented At The American Physiological Society Conference For The Institute Of Teaching And Learning .
• Cornacchione M. Unintentional Weight Loss in Long Term Care Residents with Alzheimer’s Disease and Weight Response with the Use of Docosahexaenoic Acid (DHA)/ Eicosapentaenoic Acid (EPA) and Bioflavinoids: A Pilot Study. (AMDA National , Los Angeles and International Academy on Nutrition and Aging 2011, Bologna, Italy)
• Simonson W., Cornacchione M, Johnson, D. Lansoprazole 15 mg Treatment of Frequent Heartburn Over 14 Days in Self-Treating Younger and Older Populations. Presented at the 24th National Conference of the American Academy of Nurse Practitioners; June 17 – 21, 2009; Nashville, TN
• Cornacchione M., Trombetta D., Humphrey M., et.al. An Evaluation of the Process of Erythropoietic Stimulating Agent Use in the Anemia of Chronic Kidney Disease in LTC. American Medical Directors Assoc. Meeting 2007.
• Cornacchione M., O’Brien J, Lahue B, et.al. Increased Management Needs, Functional Dependency and Staff Resources for Nursing Home Residents with Clostridium, American Geriatric Society, Chicago 2009
• AMDA Clinical Practice Guidelines: Dementia Care in LTC. American Medical Directors Association, Charlotte, NC., 2009.
• Orexigenic Agent Use in Unintended Weight Loss: Pro/Con Debate. American Medical Directors Association, Charlotte, NC., 2009.
• A Multidisciplinary Approach to Management of Chronic Constipation in Older Adults: Case Studies for Optimal Treatment. American Geriatrics Society, Chicago, IL., 2009.
• Chronic Constipation: Diagnosis & Management. Florida American Medical Directors Association, Orlando, FL., 2008.
• Chronic Constipation: Diagnosis & Management. Texas American Medical Directors Association, Dallas, TX., 2008.
• End of Life Care in Dementia, NY State Medical Directors Association Annual Meeting, Albany, NY, May 2008.
• Clinical Controversies. Moderator: Amiodarone Use in Elderly; Orexigenic Use in Unintended Weight Loss; Vitamiin D and Preventing Falls. 29th Mid Year American Society of Consulting Pharmacists. Hollywood, FL. 2007
• Alzheimer’s Disease: To Treat or Not to Treat in LTC. 31st Annual Symposium American Medical Directors Association, Salt Lake City, UT, 2008.
• Keynote Speaker/ Alzheimer’s Disease in 2007. Ethics Institute of Northeastern Pennsylvania/ Conference on Ethical Perspectives on Elder Care. 2007
• Alzheimer’s Disease: To Treat or Not to Treat in LTC. 29th Mid Year American Society of Consulting Pharmacists. Hollywood, FL. 2007
• COPD: Management in Long Term Care. 19th Annual American Society of Consulting Pharmacists. Chicago, IL. 2007
  
  

Trainings/workshops

• Geisinger Clinic, Danville, PA
  Family Medicine Residency
• University of Rochester, Rochester, NY
  Mini-Fellowship in Dementia Care
• UCLA School of Medicine, Los Angeles, CA
  California Geriatric Education Center
  Mini-Fellowship Faculty Development in Clinical Geriatric Assessment
• Mt. Sinai School of Medicine, New York, N.Y
  Department of Geriatric Medicine/Palliative Care
  Mini-Fellowship in Geriatric Medicine Education & Curriculum Development
  
  

Principal Investigator

• A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer’s Disease. 2014-present
• A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Prodromal Alzheimer’s Disease (MCI). 2014-present
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer’s Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication 2015-present
• A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab in Subjects with Early Alzheimer’s Disease (AD). 2015-present
• A Phase 3, Double Blind, Randomized Study Of RVT-101 Versus Placebo When Added To Existing Stable Donepezil Treatment In Subjects With Mild To Moderate Alzheimer’s Disease 2024-present
• A Phase 2A Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo- Controlled Study of SUVN-502 in Subjects with Moderate Alzheimer’s Disease Currently Treated with Donepezil Hydrochloride and Memantine Hydrochloride 2015-present
• An intervention to influence medical students’ attitudes and response to substance abuse within professionals. (in progress)
• IPE: InterProfessional Education, Internalizing Powerful Experiences
• Danone, Alz.1.C/C: Phase III randomized placebo controlled trail to assess the efficacy of XXX in patients with mild to moderate Alzheimer’s Disease currently using Alzheimer’s Disease Medication
• NEU AZ1, Phase II Double-Blind, parallel group, randomized, placebo-controlled study of the efficacy and safety of XXXX in patients with mild to moderate Alzheimer’s disease treated with acetylcholinesterase inhibitors
• Multicenter, Phase III Randomized Double Blind Placebo Controlled Parallel Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer’s Disease
• Multicenter double blind, placebo controlled phase III trial to evaluate the safety and tolerability of oral once daily prucalopride(R108512) solution in constipated elderly subject living in a nursing facility.
• Bristol Myers Squibb CN 156-013: A Multicenter randomized double blind placebo-controlled study to evaluate safety and efficacy of XXXX in pts with mild to moderate Alzheimer’s Disease
• Unintentional Weight Loss in Long Term Care Residents with Alzheimer’s Disease and Weight Response with the Use of Docosahexaenoic Acid (DHA)/ Eicosapentaenoic Acid (EPA) and Bioflavinoids: A Pilot Study
• An Evaluation of the Process of Erythropoietic Stimulating Agent Use in the Anemia of Chronic Kidney Disease in LTC
• Evaluation of Management Needs, Functional Dependency and Staff Resources for Nursing Home Residents with Clostridium difficile-Associated Diarrhea (CDAD)

Education

DO – New York College of Osteopathic Medicine
MS – Rutgers University
BA – Alfred University